Antiplatelet Therapy in Patients with Previous Cerebral Aneurysm
Primary Recommendation
- The American Heart Association/American Stroke Association recommends aspirin monotherapy (50-325 mg/day) as first-line antiplatelet therapy for patients with ischemic stroke or TIA and a history of cerebral aneurysm, providing stroke prevention benefits while minimizing bleeding risk 1, 2
Antiplatelet Therapy Considerations
- For patients with aspirin contraindication, clopidogrel 75 mg daily is an acceptable alternative, but should be approached cautiously in patients with cerebral aneurysms due to theoretical increased bleeding risk 1, 2, 3
- The combination of clopidogrel plus aspirin is not recommended for stroke/TIA patients due to increased major hemorrhage risk, with a 1.3% absolute increase in life-threatening bleeding 5, 1, 6, 2
- The AHA/American Stroke Association guidelines contain a Class III recommendation (harm) against combining aspirin and clopidogrel in patients with prior stroke or TIA 5, 6, 4
Special Considerations for Cerebral Aneurysm History
- Unruptured aneurysms carry increased intracranial hemorrhage risk with thrombolysis and potent antiplatelet therapy 3
- The theoretical risk of aneurysm rupture or bleeding from residual aneurysm tissue makes aggressive antiplatelet therapy particularly hazardous 3
Clinical Algorithm
- If aneurysm was previously treated (clipped/coiled), start aspirin 81-325 mg daily 1, 2
- If untreated aneurysm remains, obtain urgent neurosurgical/neurointerventional consultation before initiating any antiplatelet therapy 3
- If aspirin contraindicated, use clopidogrel 75 mg daily with extreme caution and close monitoring 1, 2